Stryker Corp (SYK) Stock AnalysisSYKStryker Corp

Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Stryker Corp is currently priced at $277.33, with a forward P/E of 16.47, indicating it may be undervalued compared to its earnings potential. However, the stock has experienced a year-to-date decline of 20.35%, and recent downgrades from analysts, including Truist lowering its price target to $310, reflect concerns about future performance. The main risk is the ongoing selling pressure from hedge funds, which has increased by 119.77% over the last quarter, indicating a lack of confidence among institutional investors.

27 analysts cover SYK: 17 rate it Buy, 8 Hold and 2 Sell. The average price target is 430.32.